Natera (NTRA) closed at $401.37 on October 22, 2026, down 2.9% from the previous close, on volume of 1,563,691 shares (30-day average 1,635,103).
Data as of October 22, 2026.
22-Oct-2026
Business Wire (Sun, 18-Oct 6:10 PM ET)
TipRanks (Sun, 18-Oct 8:31 AM ET)
Natera's Signatera MRD Test Named to TIME's List of the Best Inventions of 2026
Business Wire (Thu, 15-Oct 12:46 PM ET)
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Business Wire (Tue, 13-Oct 7:30 AM ET)
FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay
Business Wire (Fri, 9-Oct 8:00 AM ET)
Natera Announces Randomized, Signatera -Guided Interventional Study in Melanoma
Business Wire (Wed, 7-Oct 8:00 AM ET)
New Signatera Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Business Wire (Tue, 6-Oct 8:00 AM ET)
Business Wire (Mon, 5-Oct 8:00 AM ET)
Business Wire (Tue, 22-Sep 8:00 AM ET)
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
Business Wire (Fri, 18-Sep 6:00 AM ET)
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Natera trades on the NASDAQ stock market under the symbol NTRA.
As of October 22, 2026, NTRA stock price declined to $401.37 with 1,563,691 million shares trading.
NTRA has a beta of 1.03, meaning it tends to be more sensitive to market movements. NTRA has a correlation of 0.08 to the broad based SPY ETF.
NTRA has a market cap of $57.86 billion. This is considered a Large Cap stock.
Last quarter Natera reported $753 million in Revenue and -$.47 earnings per share. This beat revenue expectation by $92 million and exceeded earnings estimates by $.05.
In the last 3 years, NTRA traded as high as $437.41 and as low as $36.90.
The top ETF exchange traded funds that NTRA belongs to (by Net Assets): VTI, VB, VBK, VXF, IBB.
NTRA has outperformed the market in the last year with a price return of +114.8% while the SPY ETF gained +14.9%. NTRA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +50.2% and +1.5%, respectively, while the SPY returned +2.3% and -1.7%, respectively.
NTRA support price is $401.00 and resistance is $425.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NTRA shares will trade within this expected range on the day.